AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9290362 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronan ophthalmic solution (0.1% hyaluronic acid), instilled five times a day to the right eye
Number of subjects: 11
Study 9290362 — intervention group
Group type: COMPARATOR
Intervention: Artificial tear solutions (control group)
Number of subjects: 11
Study 7975402 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-arteriosclerosis diet containing 20 g of ichthyenic oil
Number of subjects: 0
Study 7975402 — intervention group
Group type: EXPERIMENTAL
Intervention: SPI-containing diet
Number of subjects: 0
Study 2890806 — intervention group
Group type: EXPERIMENTAL
Intervention: DL‐dihydroxyphenylserine 600 mg
Number of subjects: 2
Study 2890806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 29489078 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (low, medium, high dosages)
Number of subjects: 171
Study 29489078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study 28124381 — intervention group
Group type: EXPERIMENTAL
Intervention: Soccer training (n=19; 128±29 one‐h sessions over one year)
Number of subjects: 31
Study 28124381 — intervention group
Group type: EXPERIMENTAL
Intervention: Soccer training (n=19)
Number of subjects: 31
Study 26150502 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased hand hygiene intervention
Number of subjects: 0
Study 26150502 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased hand hygiene and face masks
Number of subjects: 0
Study 26150502 — intervention group
Group type: COMPARATOR
Intervention: Laboratory confirmation of infections by RT‐PCR
Number of subjects: 0
Study 26150502 — intervention group
Group type: COMPARATOR
Intervention: Children
Number of subjects: 0
Study 26150502 — intervention group
Group type: COMPARATOR
Intervention: Mean generation time
Number of subjects: 0
Study 23954343 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 24674
Study 23954343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24674
Study 21964714 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast track (FT) nasogastric decompression
Number of subjects: 141
Study 21964714 — intervention group
Group type: COMPARATOR
Intervention: Traditional nasogastric decompression
Number of subjects: 141
Study 18562367 — intervention group
Group type: EXPERIMENTAL
Intervention: TM Indiana Tome (Biomet, Warsaw, Indiana, USA)
Number of subjects: 200
Study 18562367 — intervention group
Group type: COMPARATOR
Intervention: Standard limited palmar incision
Number of subjects: 200
Study 16644430 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dobutamine (LDD) stress echocardiography (peak infusion 10 microg/kg/min)
Number of subjects: 66
Study 16644430 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dobutamine (LDD) stress echocardiography
Number of subjects: 66
Study 12676043 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment for migraine/headaches
Number of subjects: 30
Study 12676043 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment for nausea/vomiting
Number of subjects: 30
Study 12676043 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall reporting of clinical details in RCTs
Number of subjects: 30
Study 12676043 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of randomization
Number of subjects: 30
Study 10653203 — intervention group
Group type: EXPERIMENTAL
Intervention: Abecarnil (12 mg, three times daily)
Number of subjects: 310
Study 10653203 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (22 mg, three times daily)
Number of subjects: 310
Study 10653203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 310
Study 9015985 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimbus II mattress
Number of subjects: 0
Study 9015985 — intervention group
Group type: COMPARATOR
Intervention: Pegasus Airwave mattress
Number of subjects: 0
Study 2000798 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (cycle ergometry, 3 times per week for 1 hour)
Number of subjects: 101
Study 2000798 — intervention group
Group type: COMPARATOR
Intervention: Nonaerobic yoga (2 times per week for 1 hour)
Number of subjects: 101
Study 2000798 — intervention group
Group type: COMPARATOR
Intervention: Waiting list nonexercise control group
Number of subjects: 101
Study 6134827 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen (testoral)
Number of subjects: 48
Study 6134827 — intervention group
Group type: COMPARATOR
Intervention: Minor tranquillizer
Number of subjects: 48
Study 6134827 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgens
Number of subjects: 48
Study 6134827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 6134827 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly sessions
Number of subjects: 48
Study 6134827 — intervention group
Group type: COMPARATOR
Intervention: Monthly sessions
Number of subjects: 48
Study 30157015 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Reintegration for Socially Isolated Patients (CRISP) program, 12-week educational socialization program
Number of subjects: 91
Study 30157015 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Reintegration for Socially Isolated Patients (CRISP) program
Number of subjects: 91
Study 30157015 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 91
Study 27112723 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading of 2 unsplinted implants
Number of subjects: 18
Study 27112723 — intervention group
Group type: COMPARATOR
Intervention: Unloaded implants (control)
Number of subjects: 18
Study 25504721 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact with gay canvassers
Number of subjects: 972
Study 25504721 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact with straight canvassers
Number of subjects: 972
Study 25504721 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up experiment
Number of subjects: 972
Study 23240867 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptually rich objects (high perceptual richness, low established knowledge)
Number of subjects: 133
Study 23240867 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptually rich objects (high perceptual richness, high established knowledge)
Number of subjects: 133
Study 23240867 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptually low objects (low perceptual richness, low established knowledge)
Number of subjects: 133
Study 23240867 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptually low objects (low perceptual richness, high established knowledge)
Number of subjects: 133
Study 20522536 — intervention group
Group type: EXPERIMENTAL
Intervention: FG‐3019 (3 mg/kg)
Number of subjects: 24
Study 20522536 — intervention group
Group type: EXPERIMENTAL
Intervention: FG‐3019 (10 mg/kg)
Number of subjects: 24
Study 17616845 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-supervised patient self-management
Number of subjects: 60
Study 17616845 — intervention group
Group type: COMPARATOR
Intervention: Anticoagulation clinic (control period)
Number of subjects: 60
Study 16906395 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (EGb) 360 mg/day plus haloperidol 0.25 mg/kg/day
Number of subjects: 109
Study 16906395 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus haloperidol 0.25 mg/kg/day
Number of subjects: 109
Study 12721253 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine (740 mg/m2)
Number of subjects: 60
Study 12721253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 10719311 — intervention group
Group type: EXPERIMENTAL
Intervention: DBPCFC with egg (first dose 500 mg or less)
Number of subjects: 196
Study 10719311 — intervention group
Group type: EXPERIMENTAL
Intervention: DBPCFC with milk (first dose 500 mg or less)
Number of subjects: 196
Study 10719311 — intervention group
Group type: EXPERIMENTAL
Intervention: DBPCFC with soy (first dose 500 mg or less)
Number of subjects: 196
Study 10719311 — intervention group
Group type: EXPERIMENTAL
Intervention: DBPCFC with wheat (first dose 500 mg or less)
Number of subjects: 196
Study 10719311 — intervention group
Group type: EXPERIMENTAL
Intervention: DBPCFC with peanut (first dose 500 mg or less)
Number of subjects: 196
Study 10719311 — intervention group
Group type: EXPERIMENTAL
Intervention: DBPCFC with fish (first dose 500 mg or less)
Number of subjects: 196
Study 10719311 — intervention group
Group type: EXPERIMENTAL
Intervention: DBPCFC with milk (first dose 250 mg)
Number of subjects: 196
Study 10719311 — intervention group
Group type: EXPERIMENTAL
Intervention: DBPCFC with egg (first dose 250 mg)
Number of subjects: 196
Study 10719311 — intervention group
Group type: EXPERIMENTAL
Intervention: DBPCFC with milk (first dose 100 mg)
Number of subjects: 196
Study 10719311 — intervention group
Group type: EXPERIMENTAL
Intervention: DBPCFC with egg (first dose 100 mg)
Number of subjects: 196
Study 10719311 — intervention group
Group type: EXPERIMENTAL
Intervention: DBPCFC (final dose or open challenge) with egg
Number of subjects: 196
Study 10719311 — intervention group
Group type: EXPERIMENTAL
Intervention: DBPCFC (final dose or open challenge) with milk
Number of subjects: 196
Study 10719311 — intervention group
Group type: EXPERIMENTAL
Intervention: DBPCFC (final dose or open challenge) with soy
Number of subjects: 196
Study 10719311 — intervention group
Group type: EXPERIMENTAL
Intervention: DBPCFC (final dose or open challenge) with wheat
Number of subjects: 196
Study 10719311 — intervention group
Group type: EXPERIMENTAL
Intervention: DBPCFC (final dose or open challenge) with peanut
Number of subjects: 196
Study 10719311 — intervention group
Group type: EXPERIMENTAL
Intervention: DBPCFC (final dose or open challenge) with fish
Number of subjects: 196
Study 10719311 — intervention group
Group type: EXPERIMENTAL
Intervention: First dose reactions severity
Number of subjects: 196
Study 10719311 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of PST and RAST with dose and severity
Number of subjects: 196
Study 8658221 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus immunotherapy
Number of subjects: 0
Study 8658221 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study 8658221 — intervention group
Group type: EXPERIMENTAL
Intervention: PSK or OK‐432 (biological response modifiers) added to chemotherapy
Number of subjects: 0
Study 1329251 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UF) 15,000 units, three subcutaneous injections (Group 1)
Number of subjects: 50
Study 1329251 — intervention group
Group type: EXPERIMENTAL
Intervention: Parnaparin 6,400 units, single injection (Group 2)
Number of subjects: 50
Study 1329251 — intervention group
Group type: EXPERIMENTAL
Intervention: Parnaparin 12,800 units, single injection (Group 3)
Number of subjects: 50
Study 1329251 — intervention group
Group type: EXPERIMENTAL
Intervention: Parnaparin (both dosages)
Number of subjects: 50
Study 1329251 — intervention group
Group type: EXPERIMENTAL
Intervention: Parnaparin
Number of subjects: 50
Study 3862230 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar free chewing gum containing 0.25 mg fluoride
Number of subjects: 20
Study 3862230 — intervention group
Group type: COMPARATOR
Intervention: Sugar free chewing gum without fluoride (placebo)
Number of subjects: 20
Study 31415087 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg of fezolinetant twice daily for 12 weeks
Number of subjects: 87
Study 31415087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 28843079 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD symptom reduction
Number of subjects: 159
Study 28843079 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in hopelessness
Number of subjects: 159
Study 27364883 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted laparoscopic hysterectomy (RALH)
Number of subjects: 137
Study 27364883 — intervention group
Group type: COMPARATOR
Intervention: Total abdominal hysterectomy by laparotomy (TAH)
Number of subjects: 137
Study 24061719 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-based PSI system (group A)
Number of subjects: 50
Study 24061719 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI/X-ray-based PSI system (group B)
Number of subjects: 50
Study 24061719 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PSI systems
Number of subjects: 50
Study 23201845 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary vitamin C
Number of subjects: 420
Study 23201845 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary copper
Number of subjects: 420
Study 23201845 — intervention group
Group type: EXPERIMENTAL
Intervention: β‐carotene, vitamin E, zinc
Number of subjects: 420
Study 20839388 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine (p.o. 30 mg q.d.s., n = 8)
Number of subjects: 48
Study 20839388 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone (s.c. 0.30 mg/kg, n = 16)
Number of subjects: 48
Study 20839388 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined MNTX and codeine (same doses and routes, n = 16)
Number of subjects: 48
Study 20839388 — intervention group
Group type: COMPARATOR
Intervention: Placebo [s.c. and p.o. (orally), n = 8]
Number of subjects: 48
Study 17425495 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 16117920 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocols of randomised trials
Number of subjects: 102
Study 16117920 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistically significant outcomes
Number of subjects: 102
Study 16117920 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials with at least one primary outcome changed
Number of subjects: 102
Study 10930153 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple combination therapy including protease inhibitors (PI)
Number of subjects: 0
Study 10930153 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple combination therapy including non-nucleoside reverse transcriptase inhibitors (NNRTI)
Number of subjects: 0
Study 10930153 — intervention group
Group type: COMPARATOR
Intervention: Dual nucleoside therapy
Number of subjects: 0
Study 9058214 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited intentional normovolemic hemodilution (LINH) during the prebypass period until a hematocrit of 34% was obtained, with succinyl-linked gelatin infusion (n = 39)
Number of subjects: 71
Study 9058214 — intervention group
Group type: COMPARATOR
Intervention: Control group with no hemodilution (n = 32)
Number of subjects: 71
Study 9058214 — intervention group
Group type: EXPERIMENTAL
Intervention: LINH group (n = 39)
Number of subjects: 71
Study 9058214 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 32)
Number of subjects: 71
Study 9058214 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative use of homologous blood products
Number of subjects: 71
Study 9058214 — intervention group
Group type: COMPARATOR
Intervention: Total blood loss
Number of subjects: 71
Study 8372698 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow dawn simulation (gradually increasing illuminance over 45 min peaking at 100 lx)
Number of subjects: 16
Study 8372698 — intervention group
Group type: COMPARATOR
Intervention: Rapid dawn simulation (light rapidly increasing over a 4 s period to 100 lx)
Number of subjects: 16
Study 8372698 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 16
Study 3527407 — intervention group
Group type: EXPERIMENTAL
Intervention: levamisole, 2.5 mg/kg, 2 days of each week in addition to chemotherapy
Number of subjects: 97
Study 3527407 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 97
Study 29316902 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle tape
Number of subjects: 34
Study 29316902 — intervention group
Group type: COMPARATOR
Intervention: No ankle tape (control)
Number of subjects: 34
Study 26775184 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam and fentanyl combined as a single solution (group 2, 55 patients)
Number of subjects: 112
Study 26775184 — intervention group
Group type: COMPARATOR
Intervention: Midazolam and fentanyl administered separately (group 1, 57 patients)
Number of subjects: 112
Study 23621672 — intervention group
Group type: EXPERIMENTAL
Intervention: Canadian Occupational Performance Measure (COPM)
Number of subjects: 152
Study 23621672 — intervention group
Group type: COMPARATOR
Intervention: Gender comparison
Number of subjects: 152
Study 21551176 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder strapping applied for one month in addition to routine rehabilitation
Number of subjects: 14
Study 21551176 — intervention group
Group type: COMPARATOR
Intervention: Routine rehabilitation only
Number of subjects: 14
Study 18479744 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release metoprolol succinate (n=4174)
Number of subjects: 8351
Study 18479744 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=4177)
Number of subjects: 8351
Study 17133050 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid-based system
Number of subjects: 23
Study 17133050 — intervention group
Group type: COMPARATOR
Intervention: Conventional ultrasound
Number of subjects: 23
Study 17133050 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 23
Study 12799892 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-port technique
Number of subjects: 200
Study 12799892 — intervention group
Group type: COMPARATOR
Intervention: Four-port technique
Number of subjects: 200
Study 11218055 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 0
Study 9087975 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline in addition to levodopa
Number of subjects: 163
Study 9087975 — intervention group
Group type: COMPARATOR
Intervention: Levodopa monotherapy
Number of subjects: 163
Study 8238220 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (mean total dose, 24.8 mg; mean number of injections, 5.0 ± 1.3)
Number of subjects: 74
Study 8238220 — intervention group
Group type: COMPARATOR
Intervention: Control (no 5-fluorouracil)
Number of subjects: 74
Study 2436011 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.9 g of the amylase inhibitor
Number of subjects: 8
Study 2436011 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 g of the amylase inhibitor
Number of subjects: 8
Study 2436011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 29105313 — intervention group
Group type: EXPERIMENTAL
Intervention: Pru p 3-enriched-SLIT
Number of subjects: 0
Study 29105313 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated peach allergic patients)
Number of subjects: 0
Study 26081485 — intervention group
Group type: EXPERIMENTAL
Intervention: EAA mixture with 20% L-Leucine (Group A)
Number of subjects: 36
Study 26081485 — intervention group
Group type: EXPERIMENTAL
Intervention: EAA mixture with 40% L-Leucine (Group B)
Number of subjects: 36
Study 26081485 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group C)
Number of subjects: 36
Study 25311337 — intervention group
Group type: EXPERIMENTAL
Intervention: AdheSE non-etch (self-etch approach)
Number of subjects: 22
Study 25311337 — intervention group
Group type: COMPARATOR
Intervention: AdheSE etch (self-etch approach with selective acid-etching of enamel margins)
Number of subjects: 22
Study 23027230 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation intervention
Number of subjects: 0
Study 23027230 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no self-affirmation)
Number of subjects: 0
Study 23027230 — intervention group
Group type: EXPERIMENTAL
Intervention: Low physical self-esteem
Number of subjects: 0
Study 20823297 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppressing thoughts of thirst
Number of subjects: 0
Study 20823297 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppressing aggressive thoughts
Number of subjects: 0
Study 20823297 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppressing laughter
Number of subjects: 0
Study 20823297 — intervention group
Group type: COMPARATOR
Intervention: Belief that suppression is difficult for everybody
Number of subjects: 0
Study 20823297 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation to do the suppressed behavior
Number of subjects: 0
Study 18433921 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei Shirota (6.5 x 10(9)) 3 times daily for 4 weeks
Number of subjects: 12
Study 18433921 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (n=13)
Number of subjects: 12
Study 18433921 — intervention group
Group type: COMPARATOR
Intervention: Cirrhotic patients without probiotics (n=8)
Number of subjects: 12
Study 20076952 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg orally for 5 days)
Number of subjects: 12
Study 20076952 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 16235159 — intervention group
Group type: EXPERIMENTAL
Intervention: BIAsp 70 (70% soluble IAsp and 30% protaminated IAsp)
Number of subjects: 27
Study 16235159 — intervention group
Group type: COMPARATOR
Intervention: BIAsp 30 (30% soluble IAsp and 70% protaminated IAsp)
Number of subjects: 27
Study 16235159 — intervention group
Group type: COMPARATOR
Intervention: BIAsp 30
Number of subjects: 27
Study 16235159 — intervention group
Group type: EXPERIMENTAL
Intervention: BIAsp 70
Number of subjects: 27
Study 11801578 — intervention group
Group type: EXPERIMENTAL
Intervention: AmBisome 3 or 5 mg/kg/day
Number of subjects: 0
Study 11801578 — intervention group
Group type: COMPARATOR
Intervention: Abelcet 5 mg/kg/day
Number of subjects: 0
Study 11801578 — intervention group
Group type: COMPARATOR
Intervention: Amphocil
Number of subjects: 0
Study 11801578 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid formulations (general)
Number of subjects: 0
Study 9670875 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (T)
Number of subjects: 16
Study 9670875 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 16
Study 7869686 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial injection of diluted local anesthetic (1:10 with saline)
Number of subjects: 13
Study 7869686 — intervention group
Group type: COMPARATOR
Intervention: Full-strength 2% mepivacaine with adrenaline 1:200,000
Number of subjects: 13
Study 3794867 — intervention group
Group type: EXPERIMENTAL
Intervention: HB-PU umbilical catheters
Number of subjects: 125
Study 3794867 — intervention group
Group type: COMPARATOR
Intervention: PVC catheters
Number of subjects: 125